Fundraising Fox

Syremis Therapeutics

Founded 2025 · 6 known investors

syremis.com ↗

Syremis Therapeutics is a clinical-stage biopharmaceutical company developing neuropsychiatric medicines based on mechanisms including muscarinic M1/M4 agonism and NMDA antagonism. Its pipeline includes ST-905, a dual M1/M4 agonist in Phase 1 for schizophrenia, and ST-901, an NMDA antagonist in IND-enabling studies for major depressive disorder and bipolar depression.

BiotechHealthtechMental Health

Investors · 6

Third Rock Ventures✓ verifiedBoston · $100K – $5M
Bain Capital Life Sciencesreported · 2 sourcesBoston
GV (Google Ventures)reported · 2 sourcesMountain View · $250K – $50M

Also in the syndicate · 3

Dexcel PharmaleadPictetQVT

Funding

SEC filings, press & company announcements

$165M disclosed across 1 round · 2025

Source: company announcements and press reports — follow each round's link for the claim.

Competitors · 2

by search overlap
Bioworld8 shared keywordsBioWorld is a suite of daily news and data services covering therapeutics, medical technology, biopharma business transactions, and drug R&D, serving biopharmaceutical and medtech industry professionals. Owned by Clarivate, it publishes products including BioWorld, BioWorld Science, and BioWorld Asia with reporting from writers stationed globally.
Aclaris Therapeutics7 shared keywordsAclaris develops investigational monoclonal antibodies and small-molecule inhibitors targeting immune pathways for the treatment of atopic, autoimmune, and respiratory diseases. The company's clinical and preclinical pipeline includes candidates in development for severe asthma, atopic dermatitis, and T-cell-mediated autoimmune conditions.

Companies competing with Syremis Therapeutics for the same Google search keywords, organic and paid, via search-intersection analysis.

In the news

Syremis Therapeutics Launches With $165 Million Series A Funding To Advance New Schizophrenia And Depression Drug Programspulse2.com · Dec 2025Mental health treatment co Syremis Therapeutics raises $165m - Globesen.globes.co.il · Dec 2025Syremis raises $165 million Series A to take on schizophrenia and other severe mental illnesses | CTechcalcalistech.com · Dec 2025Lucid Diligence Brief: Syremis Therapeutics launches with $165M Series A in schizophrenia - LucidQuestlqventures.com · Dec 2025Syremis Therapeutics Raises $165M in Series A Financingfinsmes.com · Dec 2025Karuna head, Teva alums meet minds to launch schizophrenia-focused biotech Syremis with $165M series A | Fierce Biotechfiercebiotech.com · Dec 2025

Frequently asked questions

What does Syremis Therapeutics do?
Syremis Therapeutics is a clinical-stage biopharmaceutical company developing neuropsychiatric medicines based on mechanisms including muscarinic M1/M4 agonism and NMDA antagonism. Its pipeline includes ST-905, a dual M1/M4 agonist in Phase 1 for schizophrenia, and ST-901, an NMDA antagonist in IND-enabling studies for major depressive disorder and bipolar depression.
Who are Syremis Therapeutics's investors?
Syremis Therapeutics's investors include Third Rock Ventures, Bain Capital Life Sciences, GV (Google Ventures).
How much funding has Syremis Therapeutics raised?
Syremis Therapeutics has disclosed $165M raised across 1 round.